Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
7.338 / 17.032
#58698

Re: Farmas USA

AMRN
No se me carga el pre. ¿Lo tiene alguien?

#58699

Re: Farmas USA

No, yo no hago caso de los analistas, que seran todo lo profesionales que sean, es el mio......

Previo paso por el 1,61, si me lo permitis claro esta....

#58701

Re: Farmas USA

a mi me aparece 1.52 AMRN

#58703

Re: Farmas USA

Nvax
Hoy cerramos por encima de 9

#58704

Re: Farmas USA

CERS, una de cal y otra de arena....¿cual pesará más?...entré a 5,15 con media posición...

http://www.streetinsider.com/Analyst+Comments/Cerus+%28CERS%29+PT+Lowered+to+%246.50+at+Wedbush+Post+Q4%3B+Outperform+Maintained/10320545.html

http://www.streetinsider.com/Corporate+News/Cerus+Corp+%28CERS%29+Enters+INTERCEPT+Blood+System+Agreement+w+Karolinska+University+Hospital/10320909.html?si_client=intbro

http://seekingalpha.com/article/2956656-cerus-cers-ceo-william-greenman-on-q4-2014-results-earnings-call-transcript?part=single

We ended 2014 with cash and short-term investments of $51.3 million compared to $47.6 million at the end of September. In January 2015, the company completed a public offering of common stock raising more than $75 million after offering expenses. Our Oxford Finance credit facility provides up to $20 million in additional term loans, $10 million of which is conditioned upon achieving consolidated trailing 6-month revenues at specified levels. The strong year-end balance sheet, coupled with the proceeds from the January offering and the funds available under our credit facility, position the company well to execute on our initiatives, including the launch of the INTERCEPT in the United States and potentially bringing the red blood cell product to market in the EU.

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?